9 Results for "

Aβ40 aggregation

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Aβ40 aggregation" in MCE Product Catalog:

Cat. No.: HY-W594851
CAS No.: 3598-30-9
Synonyms: BPT
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Biphenyl-3′,3,4,4′-tetrol (BPT) is a potent Aβ40 aggregation inhibitor. Biphenyl-3′,3,4,4′-tetrol (BPT) can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-114508
CAS No.: 1083-30-3
Purity:  99.87%
Synonyms: 3-Phenylpropiophenone; β-Phenylpropiophenone
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Dihydrochalcone (3-Phenylpropiophenone) is a aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .
loading...
    loading...
Cat. No.: HY-149272
CAS No.: 2973377-10-3
tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ40 aggregation inhibitor with IC50s of 1.8 μM and 1.3 μM, respectively .
loading...
    loading...
Cat. No.: HY-155304
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

BuChE-IN-8 (compound 19c) is a butyrylcholinesterase (BuChE) inhibitor with an IC50 of 559 nM. BuChE-IN-8 possesses human β-secretase (BACE1) and Aβ40 aggregation inhibitory activities. BuChE-IN-8 has significant antiamnesic properties .
loading...
    loading...
Cat. No.: HY-149273
CAS No.: 1776948-12-9
hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC50=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ40 protein aggregation, with IC50 values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research .
loading...
    loading...
Cat. No.: HY-180843
CAS No.: 3105860-83-8
Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-180842
CAS No.: 3105860-84-9
MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. MAO-B-IN-50 shows good inhibitory effects on the aggregation of Aβ40/42 and Tau proteins, with overall IC50 values around 1 μM. MAO-B-IN-50 exhibits potent and selective AChE inhibition (IC50 = 1.78 μM). MAO-B-IN-50 can be used in the research of Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-P11677
Research Areas:  

Neurological Disease

CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC50 of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .
loading...
    loading...
Cat. No.: HY-182304
CAS No.: 1338489-62-5
CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) .
loading...
    loading...